Aurobindo Pharma Ltd will expand its operations in newer markets in the European Union.

The Hyderabad-based company intends to consolidate its position and presence among the top 10 companies in Europe.

The proposed expansion will not just be in new markets such as Poland and Czech Republic. There will also be portfolio expansion through targeted first day launches in orals, hormonals, penems, oncology drugs and niche injectables, among others, according to the information shared in its latest investor presentation.

“Lower generic potential in Italy, France and Spain offer future growth potential,’’ the company said. , Aurobindo started to increase its focus when it acquired the commercial operations of Actavis Plc in seven Western European countries for €30 million in 2015.

It now has operations in nine European countries with supporting infrastructure expanded presence through Actavis’ assets and established commercial and hospital sales infrastructure.

In addition to over 200 products in the pipeline, expansion of analytical testing facilities for sterile and non-sterile products will drive growth, it said. The business focus will be on high value areas including oncology and tender-based business.

The gross sales in the region had shown 104 per cent CAGR and touched ₹3,195 crore in FY15 while in the first nine months of the current quarter they were at ₹2,285 crore.

In the emerging markets too, Aurobindo plans to enhance reach in selected emerging markets of Asia Pacific, Africa and the Middle East. The focus markets include Brazil, South Africa, Ukraine and Mexico.

In the third quarter ended December 31, 2015, Aurobindo posted a net profit of ₹535 crore (against ₹384 crore in the year-ago period) on a revenue of ₹3,495 crore (₹3,166 crore).

The company’s scrip closed lower at ₹655.70 on the BSE on Friday.

Related Topics